11Jul2017 A One-Bug Drug For the Immune System? Evelo Gets $50M to Test Concept /Luke Timmerman/1/All, Cancer, Venture Capital11 Jul 2017 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.